Tony Quested at Business Weekly writes:
The company is targeting a significant Series A, having raised £750k to date – mainly from Cambridge angels. It is already working with globally recognised life science players to develop treatment options.
Founder and CEO Sheila Kissane and husband Robert Marshall, CEO of Martlet Capital, are steering the global rollout after securing initial supporting from some of Cambridge’s iconic serial entrepreneurs.